Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31460489 | 0.85 | DGAT1 (0.34) | NPC1DGAT1 | |
| SCHEMBL31459865 | 0.85 | DGAT1 (0.36) | NPC1DGAT1 | |
| SCHEMBL30706578 | 0.79 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL32671098 | 0.77 | DGAT1 (0.36) | NPC1DGAT1 | |
| SCHEMBL20399584 | 0.77 | DGAT1 (0.32) | NPC1DGAT1 | |
| SCHEMBL31663644 | 0.77 | DGAT1 (0.32) | NPC1DGAT1 | |
| SCHEMBL31518223 | 0.76 | GRIN1 (0.36) | — | |
| SCHEMBL16437423 | 0.76 | KMO (0.50) | DGAT1 | |
| SCHEMBL30706826 | 0.75 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL30709985 | 0.75 | DGAT1 (0.35) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639355-B2 | Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors | Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2023-05-02 | — | — | US | disclosed |
| US-11639355-B2 | Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors | Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2023-05-02 | — | — | US | disclosed |
| EP-3766883-A1 | IMIDAXOPYROLONE COMPOUND AND APPLICATION THEREOF | Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019174576-A1 | IMIDAXOPYROLONE COMPOUND AND APPLICATION THEREOF | 罗欣药业(上海)有限公司 | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639355-B2 | Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors | TP53, MDM2, TP53BP1 | NPC1 3625/4885DGAT1 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.